Dan Ives, Wedbush Securities global head of technology research and senior equity analyst, joins 'Squawk Box' to discuss ...

Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to break down ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

The spring home-selling season is shaping up to be a challenging one for major homebuilders amid a trade war and rising ...

Wedbush Securites, a 70-year-old financial services firm based in Los Angeles, has filed with the Securities and Exchange ...

Equities researchers at Wedbush lifted their Q4 2025 earnings per share estimates for shares of CarMax in a research note ...

If the Department of Defense goes through budget cuts as suggested by a leaked memo, Palantir Technologies (PLTR) would have ...

Investing.com -- Tesla's stock has faced continued pressure in 2025, but Wedbush analysts remain bullish, maintaining their ...

We recently compiled a list of the Top 10 AI Stocks on Wall Street’s Radar Right Now. In this article, we are going to take a ...

Avalo Therapeutics (AVTX) stock surges as Wedbush initiates with a bullish view, citing lead asset AVTX-009's potential against hidradenitis suppurativa. Read more here.

Analyst Dan Ives thinks Tesla stock could soar from current levels thanks to a potential $1 trillion catalyst.

Wedbush will sponsor its own ETFs to provide clients and investors with cost-effective, transparent investment options designed to meet modern portfolio construction needs. “ETF creation is a logical ...